Several studies have recently shown that MS/MS is a reliable method for measuring cefuroxime in critically ill patients.4, 14, 15 We improved this method by adding and implementing a validated protocol for the quantification of unbound cefuroxime in a cohort of critically ill patients with low serum albumin levels and various stages of renal failure with dialysis dependency. The gene discussed is ALB; the disease is kidney failure.